Trials / Unknown
UnknownNCT02325245
Effects of Metformin in Pre-frail Elderly
Randomized-Controlled Trial of Metformin to Prevent Frailty in Pre-frail Elderly
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Indonesia University · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effects of metformin to prevent frailty in pre-frail non-diabetic elderly. Several outcomes measured in this study are frailty status, quality of life, handgrip strength, gait speed, and serum myostatin levels. We hypothesize that metformin for 16 weeks could prevent frailty in pre-frail elderly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks. |
| DRUG | Placebo | Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks. |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-12-01
- Completion
- 2017-03-01
- First posted
- 2014-12-24
- Last updated
- 2016-09-14
Locations
1 site across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT02325245. Inclusion in this directory is not an endorsement.